Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1

Conditions

Neuroblastoma 2Wilms Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Retinoblastoma 1Glioma 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × racotumomab × Clear all
NCT02998983 2023-09-11

Racotumomab in Patients With High-risk Neuroblastoma

Laboratorio Elea Phoenix S.A.

Phase 2 Completed
39 enrolled
CNS

Neuroblastoma

NCT01598454 2015-07-29

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Laboratorio Elea Phoenix S.A.

Phase 1 Completed
15 enrolled
CNSGenitourinaryOther solid neoplasmSarcoma

Glioma, Wilms Tumor, Neuroblastoma, Retinoblastoma, Sarcoma, Ewing

NCT01240447 2014-07-10

Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients

Laboratorio Elea Phoenix S.A.

Phase 2 Completed
7 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡